丹麦医疗器械制造商可乐丽周二告诉路透社，该公司已将其在中国的商业运营人员减少了80人，且预计其在中国的业务要到2027/28财年才能实现稳定。
Coloplast has reduced its commercial operations in China by 80 people and does not expect its business there to stabilize until 2027/28, the Danish medical equipment maker told Reuters on Tuesday.
记者 Vera Dvorakova、Jesus Calero 报道 中国业务约占集团销售额的4%，已成为可乐丽最大部门造口护理业务的拖累，因国内竞争和消费者信心疲软压低了消费者自费购买造口袋的需求。
By Vera Dvorakova, Jesus Calero Forming around 4% of group sales, China has become a drag on Coloplast's largest division, ostomy care, as domestic competition and weak consumer confidence weigh on demand for ostomy bags that consumers pay out of pocket.
首席执行官 Gavin Wood 表示，可乐丽削减了库存、精简了中国组织架构并任命了新领导层，以适应艰难的市场环境。人员削减仅影响可乐丽的商业组织，其在珠海拥有750名员工的生产基地不受影响。
中国同行协飞医疗科技（301087.SZ）4月表示，已成功接管原由海外品牌占据的本地市场份额。
这些变革是更广泛计划的一部分，旨在通过组织架构调整、美国生物制品业务调整和采购节约，释放5亿丹麦克朗（约合7500万美元）资金。
Coloplast cut inventories, simplified its Chinese organisation and installed new leadership while adjusting to difficult market conditions, chief executive Gavin Wood said The staff reductions affected only Coloplast's commercial organisation, leaving its 750-person production site in Zhuhai unaffected Chinese peer Cofoe Medical Technology (301087.SZ) said in April it had managed to take over local market share formerly occupied by overseas brands The changes are part of a broader programme to free up 500 million Danish crowns ($75 million) through organisational changes, adjustments to the company's US Biologics business and procurement savings